Kidney Neoplasms

"Kidney Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancers of the KIDNEY.

Descriptor ID	D007680
MeSH Number(s)	C04.588.945.947.535 C12.758.820.750 C12.777.419.473 C13.351.937.820.535 C13.351.968.419.473
Concept/Terms	Kidney Neoplasms Kidney Neoplasms Kidney Neoplasm Neoplasm, Kidney Renal Neoplasms Neoplasm, Renal Neoplasms, Renal Renal Neoplasm Neoplasms, Kidney Cancer of Kidney Cancer of Kidney Kidney Cancers Renal Cancer Cancer, Renal Cancers, Renal Renal Cancers Cancer of the Kidney Kidney Cancer Cancer, Kidney Cancers, Kidney

Below are MeSH descriptors whose meaning is more general than "Kidney Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Urologic Neoplasms [C04.588.945.947]
Kidney Neoplasms [C04.588.945.947.535]
Male Urogenital Diseases [C12]
Urogenital Neoplasms [C12.758]
Urologic Neoplasms [C12.758.820]
Kidney Neoplasms [C12.758.820.750]
Urologic Diseases [C12.777]
Kidney Diseases [C12.777.419]
Kidney Neoplasms [C12.777.419.473]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Urogenital Neoplasms [C13.351.937]
Urologic Neoplasms [C13.351.937.820]
Kidney Neoplasms [C13.351.937.820.535]
Urologic Diseases [C13.351.968]
Kidney Diseases [C13.351.968.419]
Kidney Neoplasms [C13.351.968.419.473]

Below are MeSH descriptors whose meaning is more specific than "Kidney Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Kidney Neoplasms" by people in this website by year, and whether "Kidney Neoplasms" was a major or minor topic of these publications.

Bar chart showing 323 publications over 31 distinct years, with a maximum of 21 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	5	1	6
1996	2	0	2
1997	8	1	9
1998	4	2	6
1999	6	0	6
2000	4	0	4
2001	5	0	5
2002	4	0	4
2003	4	1	5
2004	4	3	7
2005	8	2	10
2006	5	0	5
2007	14	2	16
2008	13	2	15
2009	10	2	12
2010	10	2	12
2011	10	0	10
2012	8	0	8
2013	12	0	12
2014	12	2	14
2015	14	1	15
2016	11	0	11
2017	12	4	16
2018	11	0	11
2019	13	0	13
2020	19	2	21
2021	12	2	14
2022	18	1	19
2023	12	0	12
2024	17	3	20
2025	3	0	3

Below are the most recent publications written about "Kidney Neoplasms" by people in Profiles.

Gurram S, Egan J, Antony M, Ahdoot MA, Yerram NK, Lebastchi AH, Chalfin HJ, Gomella PT, Bratslavsky G, Metwalli AR, Linehan WM, Ball MW. Renal Function After Partial Nephrectomy: A Comparative Analysis of Warm, Cold, and No Ischemia Methods. Urol Pract. 2025 05; 12(3):325-334.

View in: PubMed
Zarrabi KK, Vaishampayan U, Barata PC. Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2024 Dec; 10(6):879-881.

View in: PubMed
King AJ, Steenkamp R, Graumann O, Wah TM, Alcorn D, Nielsen TK, de Kerviler E, Zondervan PJ, Walkden M, Lagerveld B, Van Strijen M, Keeley FX, Breen DJ. Risk Factors for Residual Unablated Tumour Following CT-Guided Percutaneous Renal Cryoablation: Lessons from the EuRECA Registry. Cardiovasc Intervent Radiol. 2025 Feb; 48(2):196-204.

View in: PubMed
Hrizat AS, Lin R, Eberle-Singh J, O'Neill R, Xia Y, Testa JR, Uzzo R, McCue PA, Yang H, Li L. Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. Pathol Res Pract. 2025 Feb; 266:155774.

View in: PubMed
Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Kaimakliotis H, Sankin A, Singla N, Meads A, Burger B, Raju S, Louie MJ, Chamie K, Weizer A, Schoenberg M. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J Urol. 2025 Mar; 213(3):313-322.

View in: PubMed
Lasmanovich R, Shvero A, Kleinmann N. Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance. Curr Opin Urol. 2025 Jan 01; 35(1):68-74.

View in: PubMed
Vlachou E, Hoffman-Censits J, Singla N. The biologic landscape and therapeutic implications of upper tract urothelial cancer. Curr Opin Urol. 2025 Jan 01; 35(1):89-95.

View in: PubMed
Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barth?l?my P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Gr?nwald V. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. J Clin Oncol. 2025 Jan 10; 43(2):189-200.

View in: PubMed
Monda SM, Carney BW, May AM, Gulati S, Salami SS, Chandrasekar T, Keller ET, Huebner NA, Palapattu GS, Dall'Era MA. Differences?in mutations across tumour sizes in clear-cell renal cell carcinoma. BJU Int. 2025 Feb; 135(2):269-278.

View in: PubMed
Iskandar AS, Zarrabi KK, Tester WJ. Renal cell carcinoma: entering the age of biomarkers. Can J Urol. 2024 Aug; 31(4):11921-11930.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement